All In Biotech

Drug Trial Radar · NCT00633256

The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers

The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers.

Last checked: Nov 20, 2026Latest source record: Apr 11, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

20

Actual

Start

Dec 2006

Primary completion

Feb 2008

Study completion Feb 2008

Sponsor

Lead sponsor
Yale UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
VA Connecticut Healthcare System
First posted
Mar 11, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Factorial
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A total of 20 subjects will participate in this four week, between groups, double-blind, placebo controlled study. Subjects will participate in two experimental sessions separated by approximately one week. Subjects will be randomized to receive either 50 mg cycloserine or placebo combined with cue exposure. Several physiological and subjective outcome measures (e.g., heart rate, blood pressure, galvanic skin response) will be obtained during the sessions. Experimental sessions will last approximately 4.5 hours with follow-up sessions lasting approximately thirty minutes. Our aims are: 1. To examine the effect of cycloserine vs. placebo on extinction of smoking cue reactivity in overnight abstinent smokers. Reactivity to smoking cues will be captured with self-report smoking urges and physiological measures (heart rate, blood pressure, and skin conductance). We hypothesize that cycloserine, relative to placebo, will facilitate extinction of smoking cue reactivity. 2. To examine the effect of cycloserine vs. placebo when combined with two 4.5 hour laboratory cue exposure training sessions, on smoking behavior in smokers. Smoking behavior will be measured with self-report smoking and saliva cotinine levels. 3. To examine the effect of cycloserine vs. placebo on memory performance in nicotine dependent smokers. Memory performance will be measured with verbal learning, recognition and recall tasks. 4\) To examine the safety and tolerability of cycloserine treatment in smokers. We hypothesize that cycloserine will be well tolerated by smokers.

Conditions

  • Smoking

Interventions

  • CycloserineDrug

    50 mg Cycloserine given in two separate experimental sessions separated by approximately one week.

  • PlaceboDrug

    Matched placebo for subjects randomized to placebo arm. Given in two experimental sessions separated by approximately one week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cigarettes Smoked Per DayTime frame: 1 week follow-up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West Haven VA

    West Haven, Connecticut

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.